NCT06182527

Brief Summary

This research project aims to investigate the everyday relevance of reactive hypoglycemia (hypoglycemia after a glucose load) in the oral glucose tolerance test (OGTT). Therefore, blood glucose profiles in everyday life will be examined using continuous glucose measurement (Free Style Libre PRO IQ system) over a period of 14 days in affected persons.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 27, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 27, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

December 27, 2023

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 22, 2025

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 12, 2025

Completed
Last Updated

December 10, 2025

Status Verified

December 1, 2025

Enrollment Period

1.6 years

First QC Date

November 27, 2023

Last Update Submit

December 3, 2025

Conditions

Keywords

Reactive HypoglycemiaOral glucose tolerance testContinuous glucose monitoring

Outcome Measures

Primary Outcomes (3)

  • Occurrence of hypoglycemia

    Occurrence of glucose levels below 70 mg/dl assessed by CGM.

    14 days

  • Frequency of hypoglycemia

    Number of glucose levels below 70 mg/dl assessed by CGM.

    14 days

  • Severity of hypoglycemia

    Non-severe hypoglycemia defined as glucose levels \< 70 mg/dl but \>= 54mg/dl; severe hypoglycemia defined as glucose levels \< 54mg/dl assessed by CGM.

    14 days

Secondary Outcomes (7)

  • Time of occurence of hypoglycemia

    14 days

  • Perception of hypoglycemia

    14 days

  • Time in predefined glucose ranges

    14 days

  • Mean glucose levels

    14 days

  • Glucose variability

    14 days

  • +2 more secondary outcomes

Study Arms (1)

CGM Group

EXPERIMENTAL

Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded. In addition perception of hypoglycemia and counter action will be assessed.

Device: Free Style Libre Pro IQ

Interventions

Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.

CGM Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • hypoglycemia during a 75 g oral glucose tolerance test defined as glucose level below 70 mg/dl at timepoint 180 min.
  • written consent

You may not qualify if:

  • diabetes mellitus
  • use of medication interfering with glucose metabolism (steroid, antidiabetic medications)
  • surgery of upper GI-tract
  • known plaster allergies
  • any other clinical condition that would endanger participants safety or question scientific success according to the physicians opinion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universityhospital Ulm

Ulm, 89081, Germany

Location

MeSH Terms

Conditions

Hypoglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Martin Heni, Prof.

    University Hospital Ulm

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Every participant receives a Freestyle Libre PRO IQ Sensor, a system which ensures blinding of the glucose levels to the participants.
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Martin Heni

Study Record Dates

First Submitted

November 27, 2023

First Posted

December 27, 2023

Study Start

December 27, 2023

Primary Completion

July 22, 2025

Study Completion

August 12, 2025

Last Updated

December 10, 2025

Record last verified: 2025-12

Locations